What is the present valuation and projected CAGR of the pediatric brain tumors market?
The pediatric brain tumor market size has grown strongly in recent years. It will grow from $1.4 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to the increasing incidence of pediatric brain tumors, emerging economies, growing investment in research and development, and growing demand for diagnostic technology, and the cases of pediatric tumors are increasing globally.
The pediatric brain tumor market size is expected to see strong growth in the next few years. It will grow to $1.83 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to precision medicine, molecular profiling, targeted therapy, rising healthcare infrastructure, and extended insurance coverage. Major trends in the forecast period include the advancements in magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT) scanning technologies, the use of genetic and molecular profiling, the development of targeted therapies, the introduction of immunotherapies, the rise of minimally invasive surgical techniques.
Get Your Free Sample of The Global Pediatric Brain Tumors Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21248&type=smp
What key drivers have fueled the pediatric brain tumors market’s development over the years?
The growing demand for personalized medicine is expected to propel the growth of the pediatric brain tumors market going forward. Personalized medicine is a healthcare strategy that customizes treatments and medical decisions according to a person’s genetic makeup, lifestyle, and unique health requirements. The demand for personalized medicine rises due to advancements in genetic research, improved diagnostic tools, and the potential for more effective and targeted treatments. Personalized medicine enables targeted therapies that are more effective and cause less damage to healthy tissue by tailoring treatments to the child’s specific tumor type, mutation, and response, it enhances outcomes and reduces side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, growing demand for personalized medicine is driving the growth of the pediatric brain tumor market.
What is the segmentation for the pediatric brain tumors market?
The pediatric brain tumors market covered in this report is segmented –
1) By Type: Gliomas, Mixed Neuronal-Glial Tumors, Embryonal Tumors, Choroid Plexus Papilloma Or Carcinoma, Tumors Arising From Non-Neuroepithelial Tissue, Meningeal Tumors
2) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy
3) By Diagnosis Method: Imaging Techniques, Biopsy, Neurological Exam, Lumbar Puncture
4) By Age Group: Infants, Toddlers, Children, Adolescents
5) By Application: Hospitals And Clinics, Medical Research Centers, Academic Institutes, Other Applications
Subsegments:
1) By Gliomas: Low-Grade Gliomas, High-Grade Gliomas
2) By Mixed Neuronal-Glial Tumors: Gangliogliomas, Dysembryoplastic Neuroepithelial Tumors (DNET)
3) By Embryonal Tumors: Medulloblastoma, Atypical Teratoid Rhabdoid Tumor (ATRT), Primitive Neuroectodermal Tumors (PNET)
4) By Choroid Plexus Papilloma or Carcinoma: Choroid Plexus Papilloma, Choroid Plexus Carcinoma
5) By Tumors Arising from Non-Neuroepithelial Tissue: Rhabdomyosarcoma, Ewing’s Sarcoma
6) By Meningeal Tumors: Meningiomas, Hemangiopericytomas
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/pediatric-brain-tumors-global-market-report
Who are the most influential companies in the pediatric brain tumors market?
Major companies operating in the pediatric brain tumors market are AbbVie Inc., Bayer AG, Novartis AG, Roche Holding AG, Takeda Pharmaceutical Company, UCLA Health, Ipsen Pharma, Novocure, Blueprint Medicines, Karyopharm Therapeutics Inc., Renaissance Pharma, Servier Laboratories, Matica Biotechnology, Curis Inc., Oncoheroes Biosciences, Treovir Inc., Plus Therapeutics Inc., Stemline Therapeutics Inc., BrainChild Bio Inc., Seattle Children’s Therapeutics
What are the top industry trends projected to impact the pediatric brain tumors market?
Major companies operating in the pediatric brain tumors market are focusing on developing advanced treatments such as type II RAF inhibitors to enhance targeted therapies and improve patient outcomes. Type II RAF inhibitors are targeted therapies that focus on inhibiting RAF kinases, specifically those with mutations that drive tumor growth. These inhibitors are designed to target abnormal RAF protein structures found in certain pediatric low-grade glioma (pLGG) subtypes, effectively blocking the faulty signaling pathways that contribute to tumor cell proliferation and survival. For instance, in April 2024, Day One Biopharmaceuticals, a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for OJEMDA (tovorafenib) for the treatment of relapsed or refractory pediatric low-grade glioma (pLGG) in patients aged 6 months and older with specific BRAF alterations. This approval makes OJEMDA the first FDA-approved therapy targeting BRAF fusions or mutations in this patient population. The approval is based on the reported overall response rate of 51% from the FIREFLY-1 clinical trial, which assessed the drug’s efficacy in this indication. It is specifically targeted towards children with brain tumor that has not responded to previous treatments.
What are the major regional insights for the pediatric brain tumors market, and which region holds the top position?
North America was the largest region in the pediatric brain tumors market in 2024. The regions covered in the pediatric brain tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Pediatric Brain Tumors Market Report 2025 Offer?
The pediatric brain tumors market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Pediatric brain tumors are abnormal growths of cells in the brain or central nervous system (CNS) of children. These tumors can be benign (non-cancerous) or malignant (cancerous) and can originate in different parts of the brain or spinal cord. The goal of treatment is to shrink or remove the tumor, relieve symptoms, and preserve cognitive and motor functions, ensuring the child’s long-term health and development.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21248
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
